Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 2,665 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Completed Phase 2 Interventional Results available

Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid

NCT00742417
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Albutein 5%, Control
Biological · Other
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Whiting, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer

NCT03032250
View directory record Official record
Conditions
Caregiver, Malignant Head and Neck Neoplasm, Paranasal Sinus Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage I Hypopharyngeal Squamous Cell Carcinoma, Stage I Laryngeal Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Hypopharyngeal Squamous Cell Carcinoma, Stage II Laryngeal Squamous Cell Carcinoma, Stage II Lip and Oral Cavity Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Squamous Cell Carcinoma, Stage III Lip and Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma, Stage IV Laryngeal Squamous Cell Carcinoma, Stage IV Lip and Oral Cavity Squamous Cell Carcinoma, Stage IV Oropharyngeal Squamous Cell Carcinoma, Stage IVA Hypopharyngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Hypopharyngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Squamous Cell Carcinoma, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Hypopharyngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Squamous Cell Carcinoma, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal SCC, Recurrent Paranasal Sinus Squamous Cell Carcinoma
Interventions
Communication Intervention, Watch video, Module completion of the Prepare to Care kit, Quality-of-Life Assessment, Survey Administration, Salivary cortisol collection
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

FL-REACH: Pilot Trial of a Brief Dementia Caregiver Intervention

NCT04956874
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
FL-REACH
Behavioral
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 89 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 22, 2026, 7:19 AM EDT
Terminated Phase 2 Interventional Results available

FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma

NCT03906448
View directory record Official record
Conditions
Astrocytoma, Grade II, Astrocytoma, Grade III
Interventions
TTFields with adjuvant temozolomide
Combination Product
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Gainesville, Florida • Tampa, Florida • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Not applicable Interventional

A Conversational Agent (Cecebot) to Improve Insomnia in Stage I-III Breast Cancer Survivors

NCT06392789
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Insomnia
Interventions
Cognitive Behavior Therapy for Insomnia, Internet-Based Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Text Message-Based Navigation Intervention
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 22, 2026, 7:19 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Diabetes Inspired Culinary Education (DICE): Culinary Medicine Intervention for At-Risk Youth With Type 1 Diabetes

NCT07084805
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Diabetes Inspired Culinary Education (DICE) - Phase 1, Diabetes Inspired Culinary Education (DICE) - Phase 2
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
8 Years to 14 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 22, 2026, 7:19 AM EDT
Terminated Phase 2 Interventional

Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

NCT02728388
View directory record Official record
Conditions
NEUROFIBROMATOSIS 1
Interventions
aminolevulinic acid
Drug
Lead sponsor
Donald Basel
Other
Eligibility
14 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

NCT05298254
View directory record Official record
Conditions
Herpes Simplex
Interventions
Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3, HSV formulation 1 with adjuvant 1, HSV formulation 2 with adjuvant 1, HSV formulation 3 with adjuvant 1, HSV formulation 1 with adjuvant 2, HSV formulation 2 with adjuvant 2, HSV formulation 3 with adjuvant 2, Placebo, HSVTI_F1, HSVTI_F2
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
505 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Wichita, Kansas • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Phase 2 Interventional

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

NCT01087151
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
ABT-263, rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
48
States / cities
Alhambra, California • Antioch, California • Berkeley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Results available

Trial II of Lung Protection With Azithromycin in the Preterm Infant

NCT00319956
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
Hubert Ballard
Other
Eligibility
Up to 72 Hours
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Ocular Rinse Volume on Surface Irritation After Intravitreal Injections

NCT05615805
View directory record Official record
Conditions
Intravitreal Injection, Ocular Rinse, Age-Related Macular Degeneration, Diabetic Macular Edema, Cystoid Macular Edema
Interventions
OSDI questionnaire, SPEEDII questionnaire
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 100 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Not applicable Interventional

Older Veterans EmpoweRed To Use Regular Exercise (OVERTURE) II

NCT03580551
View directory record Official record
Conditions
Quality of Life, Aging
Interventions
Intervention Group, Waitlist Control Group
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
65 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 22, 2026, 7:19 AM EDT
Active, not recruiting Not applicable Interventional

Diet and Exercise Interventions Among Men With Prostate Cancer (Prostate 8-II)

NCT03999151
View directory record Official record
Conditions
Prostate Cancer
Interventions
Exercise and Diet
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

LIPIDS-P Trial Phase I/II Trial

NCT03405870
View directory record Official record
Conditions
Sepsis, Severe, Septic Shock
Interventions
Smoflipid
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 22, 2026, 7:19 AM EDT
Recruiting Phase 2 Interventional

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

NCT06671054
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
AP1189, 40 mg, AP1189, 70 mg, AP1189, 100 mg, AP1189 matching placebo
Drug
Lead sponsor
SynAct Pharma Aps
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Cutler Bay, Florida • Miami, Florida • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Not applicable Interventional

A Randomized Controlled Trial (RCT) of Carbon Dioxide Versus Air Insufflation During Endoscopic Retrograde Cholangiopancreatography (ERCP)

NCT00685386
View directory record Official record
Conditions
Cholestasis
Interventions
CO2 insufflation, Room air insufflation
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Results available

Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

NCT01471106
View directory record Official record
Conditions
Breast Cancer
Interventions
Dasatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 22, 2026, 7:19 AM EDT
Terminated Phase 3 Interventional Results available

Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer

NCT00088907
View directory record Official record
Conditions
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
Interventions
docetaxel, placebo, gefitinib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Phase 2 Interventional

Safety Study of Hemospan® in Prostatectomy Patients

NCT00425334
View directory record Official record
Conditions
Blood Loss, Surgical, Prostate Cancer, Surgery
Interventions
Hemospan (MP4OX), Ringer's lactate
Drug
Lead sponsor
Sangart
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Oct 22, 2026, 7:19 AM EDT
Terminated Phase 2 Interventional Results available

Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery

NCT00543309
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
nesiritide, milrinone, placebo
Drug
Lead sponsor
John M Costello
Other
Eligibility
Not listed
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

NCT01928329
View directory record Official record
Conditions
Type I Diabetes
Interventions
Exenatide (Bydureon®), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Phase 2 Interventional

Study to Determine the Effects Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region

NCT01083875
View directory record Official record
Conditions
Oral Mucositis
Interventions
amlexanox, Vehicle rinse
Drug
Lead sponsor
Access Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Mobile, Alabama • Little Rock, Arkansas • Bakersfield, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2010 · Synced Oct 22, 2026, 7:19 AM EDT
Recruiting Phase 2 Interventional

Horizon Two: HR NDMM (MMRC-100)

NCT07053436
View directory record Official record
Conditions
High Risk Newly Diagnosed Multiple Myeloma
Interventions
Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
12
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 7:19 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

COVID-19 Rapid Test-to-Treat With African American Churches (Faithful Response II)

NCT07450209
View directory record Official record
Conditions
COVID-19 Testing Behaviors
Interventions
COVID-19 rapid test-to-treat, Standard COVID19 education control arm
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years to 120 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 22, 2026, 7:19 AM EDT